Whitehawk Therapeutics (WHWK) director receives 38,040 stock options at $4.16

Rhea-AI Filing Summary

Whitehawk Therapeutics director Neil Desai received a new stock option grant. The Form 4 shows an award of options covering 38,040 shares of common stock at an exercise price of $4.1600 per share, expiring on June 12, 2036.

All 38,040 option shares vest in a single tranche, subject to Mr. Desai continuing as a service provider. Vesting occurs on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting after that grant date.

Insights

Equity Compensation Analyst

Routine director stock option grant with time-based vesting.

The Form 4 shows director Neil Desai receiving 38,040 stock options for Whitehawk Therapeutics common shares at an exercise price of $4.1600. This is coded as an "A" transaction, indicating a grant or award rather than an open-market trade.

The options vest 100% on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day before the next annual stockholder meeting after that date, assuming continued service. The filing shows 38,040 derivative securities held after the transaction, suggesting a straightforward, time-based equity incentive with no immediate cash outlay or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Desai Neil

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 38,040 shares (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

Key Figures

Options granted: 38,040 options Exercise price: $4.1600 per share Underlying shares: 38,040 shares +3 more

6 metrics

Options granted 38,040 options Stock Option (right to buy) grant to director

Exercise price $4.1600 per share Stock option exercise price for underlying common stock

Underlying shares 38,040 shares Common stock underlying the granted options

Expiration date June 12, 2036 Option expiration for the granted stock options

Vesting schedule 100% cliff vest Earlier of 1-year after June 12, 2026 or pre-next annual meeting

Post-transaction derivative holdings 38,040 derivatives Total derivative securities held after the grant

Key Terms

Stock Option (right to buy), exercise price, Service Provider, Equity Incentive Plan

4 terms

Stock Option (right to buy) financial

"The Form 4 shows an award of options covering 38,040 shares of common stock."

exercise price financial

"options covering 38,040 shares of common stock at an exercise price of $4.1600 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider through such applicable date"

Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 05:22 PM Accepted by SEC EDGAR 06/15/2026 - 05:22 PM Learn about SEC filing dates

FAQ

What did Neil Desai report in his Whitehawk Therapeutics (WHWK) Form 4?

Neil Desai reported receiving a grant of stock options for 38,040 shares of Whitehawk Therapeutics common stock. These options were awarded at an exercise price of $4.1600 per share and are scheduled to expire on June 12, 2036, if not exercised earlier.

Is the Form 4 transaction for Whitehawk Therapeutics (WHWK) a purchase or a grant?

The Form 4 reflects a grant or award, not an open-market purchase. It is coded as transaction type "A" for 38,040 stock options, meaning the director received derivative securities as compensation rather than buying shares in the market.

What are the vesting terms of Neil Desai’s Whitehawk Therapeutics stock options?

All 38,040 option shares vest 100% in a single tranche, provided Neil Desai remains a service provider. Vesting occurs on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting afterward.

What is the exercise price and expiration date of the WHWK options granted to Neil Desai?

The stock options have an exercise price of $4.1600 per share and an expiration date of June 12, 2036. This gives a long-dated window for potential exercise once the options are vested and subject to continued service conditions.

How many derivative securities does Neil Desai hold after this Whitehawk Therapeutics grant?

Following this reported grant, the filing shows Neil Desai holding 38,040 derivative securities related to Whitehawk Therapeutics common stock. These correspond to the newly granted stock options, each representing the right to buy one share at the specified exercise price.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Desai Neil

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)